CN1756542A - Use of L-dopa, derivatives thereof and medicaments containing said compounds for the prevention of psychotic disorders - Google Patents
Use of L-dopa, derivatives thereof and medicaments containing said compounds for the prevention of psychotic disorders Download PDFInfo
- Publication number
- CN1756542A CN1756542A CNA2003801066148A CN200380106614A CN1756542A CN 1756542 A CN1756542 A CN 1756542A CN A2003801066148 A CNA2003801066148 A CN A2003801066148A CN 200380106614 A CN200380106614 A CN 200380106614A CN 1756542 A CN1756542 A CN 1756542A
- Authority
- CN
- China
- Prior art keywords
- dopa
- physiological compatibility
- derivant
- inhibitor
- compatibility salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims abstract description 36
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims description 16
- 208000028017 Psychotic disease Diseases 0.000 title claims 3
- 230000002265 prevention Effects 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 10
- 108010035075 Tyrosine decarboxylase Proteins 0.000 claims abstract description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002532 enzyme inhibitor Substances 0.000 claims abstract description 7
- 241001597008 Nomeidae Species 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 10
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims description 9
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical group OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 9
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 9
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 7
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims description 6
- 229940087098 Oxidase inhibitor Drugs 0.000 claims description 6
- -1 5-pentyl pyridine calcium formate Chemical compound 0.000 claims description 5
- 229960004205 carbidopa Drugs 0.000 claims description 5
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 5
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 5
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 4
- BUZLUQORXILCMY-LBPRGKRZSA-N (2s)-2-amino-3-(4-hydroxyphenyl)-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical class C([C@H](N)C(=O)NNCC=1C(=C(O)C(O)=CC=1)O)C1=CC=C(O)C=C1 BUZLUQORXILCMY-LBPRGKRZSA-N 0.000 claims description 4
- BNQDCRGUHNALGH-LURJTMIESA-N (2s)-2-amino-3-hydroxy-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical class OC[C@H](N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-LURJTMIESA-N 0.000 claims description 4
- VEWUMDXDCNJDHA-UHFFFAOYSA-N 2-amino-n'-[(2,3,4-trihydroxyphenyl)methyl]acetohydrazide Chemical class NCC(=O)NNCC1=CC=C(O)C(O)=C1O VEWUMDXDCNJDHA-UHFFFAOYSA-N 0.000 claims description 4
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 4
- XNCRUNXWPDJHGV-UHFFFAOYSA-N alpha-Methyl-cinnamic acid Chemical class OC(=O)C(C)=CC1=CC=CC=C1 XNCRUNXWPDJHGV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000911 benserazide Drugs 0.000 claims description 4
- 229960004596 cabergoline Drugs 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229960003337 entacapone Drugs 0.000 claims description 4
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004644 moclobemide Drugs 0.000 claims description 4
- 229960003741 tranylcypromine Drugs 0.000 claims description 4
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 3
- 229960003946 selegiline Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 208000020016 psychiatric disease Diseases 0.000 abstract description 5
- 239000000654 additive Substances 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010025482 malaise Diseases 0.000 description 9
- 230000003340 mental effect Effects 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 239000003513 alkali Substances 0.000 description 7
- 239000012752 auxiliary agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940087613 comtan Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960003678 selegiline hydrochloride Drugs 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The invention relates to the use of L-dopa, derivatives thereof or their physiologically compatible salts for the prophylaxis of psychiatric disorders and for the treatment of diseases which are caused by a disturbed tyrosine transport or a disturbed tyrosine decarboxylase. In addition, the present invention relates to a pharmaceutical composition comprising L-dopa, derivatives thereof or physiologically compatible salts thereof for the prevention of psychiatric disorders in addition to pharmaceutically compatible adjuvants and additives. Furthermore, the invention relates to the combination of L-dopa, derivatives thereof or their physiologically compatible salts with enzyme inhibitors for the prevention of psychiatric disorders and for the treatment of diseases which are caused by a disturbed tyrosine transport or a disturbed tyrosine decarboxylase, and to corresponding pharmaceutical compositions for the prevention of psychiatric disorders and for the treatment of diseases which are caused by a disturbed tyrosine transport or a disturbed tyrosine decarboxylase.
Description
The present invention relates to 3,4-dihydroxy-L-phenylalanine (L-DOPA) and its derivant are used to prepare the purposes of medicine, and they are used to prevent mental sickness and are used for the treatment of because the purposes of the disease that the tyrosine decarboxylase of disorderly tyrosine transhipment or disorder causes.
At present, usually treat the symptom of schizophrenia disease by means of neuroleptic such as chlorpromazine, haloperidol, sulpiride and chemical analog thereof.Because use the treatment of neuroleptic can not cure underlying diseases, so therapy discontinued can cause patient's recurrence usually.
Different mental sickness is all relevant with the dysbolismus of norepinephrine, dopamine and 5-hydroxy tryptamine.
L-DOPA and its derivant particularly ester are particularly useful for treating parkinson disease and restless leg syndrome so far.The L-DOPA affects the dopamine level in the cranial nerve cell.Different with dopamine itself, the L-DOPA can pass through blood brain barrier, and is transformed into dopamine in brain.
The L-DOPA gives in the medicine that has active additive usually.Particularly can use the combination of the inhibitor of the inhibitor of inhibitor, monoamine oxidase, MAO (MAO) of L-DOPA and periphery decarboxylase inhibitor, catechol O-methyltransferase (COMT) and dopamine-.
The relevant therewith decarboxylase inhibitor of using for example is D, L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides (benserazide), (-)-L-a-diazanyl-3,4-dihydroxy-a-hydrogenated methyl cinnamic acid (carbidopa), L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides, glycine-2-(2,3,4-trihydroxy benzyl) hydrazides and L-tyrosine-2-(2,3,4-trihydroxy benzyl) hydrazides.The example of the combination preparation of being made up of L-DOPA and decarboxylase inhibitor is Madopar (L-DOPA and Ro-4-4602 .) and Nacom (L-DOPA and carbidopa) especially.
The example of COMT inhibitor is that entacapone (Comtan ) and cabergoline are SelegilineHydrochloride, moclobemide and tranylcypromine with MAO inhibitor commonly used.
As the inhibitor of dopamine-, describing has 5-butyl picolinate calcium and 5-pentyl pyridine calcium formate (DE-A 2 049 115).
Be preferred for preventing the purposes of the recurrence of mental sickness according to the present invention, be meant the recurrence of schizophrenia disease especially.
Be surprisingly found out that, the L-DOPA can be used to prevent mental sickness.If known can produce the side effect of mental disorder when the L-of administered with high dose DOPA the time, this just more makes us surprised.
At this, preferably unite and use L-DOPA, its derivant and their physiological compatibility salt and one or more to be used to prevent mental sickness and be used for the treatment of because disorderly tyrosine is transported or the enzyme inhibitor of the disease that the tyrosine decarboxylase of disorder causes.
If enzyme inhibitor is decarboxylase inhibitor and/or catechol O-methyltransferase inhibitor and/or oxidase inhibitor and/or B-hydroxylase inhibitors, this is favourable so.
If decarboxylase inhibitor is selected from D, L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides (benserazide), (-)-L-a-diazanyl-3,4-dihydroxy-a-hydrogenated methyl cinnamic acid (carbidopa), L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides, glycine-2-(2,3,4-trihydroxy benzyl) hydrazides and L-tyrosine-2-(2,3,4-trihydroxy benzyl) hydrazides with and physiological compatibility salt, this is particularly advantageous so.
In addition, if the catechol O-methyltransferase inhibitor be selected from entacapone and cabergoline with and physiological compatibility salt, this is particularly advantageous so.
If oxidase inhibitor be selected from selegiline, moclobemide and tranylcypromine with and physiological compatibility salt, this also is particularly advantageous so.
If B-hydroxylase inhibitors be selected from 5-butyl picolinate calcium and 5-pentyl pyridine calcium formate with and physiological compatibility salt, this is further particularly advantageous so.
Another target of the present invention is the purposes that L-DOPA, its derivant and their physiological compatibility salt are used to prepare medicine, and this medicine is used to prevent mental sickness and is used for the treatment of the disease that causes owing to disorderly tyrosine transhipment or disorderly tyrosine decarboxylase.
Another one target of the present invention is a kind of pharmaceutical composition, it also contains and is useful on the prevention mental sickness and is used for the treatment of because L-DOPA, its derivant and their the physiological compatibility salt of the disease that the tyrosine decarboxylase of disorderly tyrosine transhipment or disorder causes except containing drug compatibility auxiliary agent and additive.
Particularly preferably be such pharmaceutical composition at this, it is except containing drug compatibility auxiliary agent and additive, also contain and be useful on the prevention mental sickness and be used for the treatment of because L-DOPA, its derivant and their physiological compatibility salt and one or more enzyme inhibitors of the disease that the tyrosine decarboxylase of disorderly tyrosine transhipment or disorder causes.
Such pharmaceutical composition is particularly preferred, and promptly wherein enzyme inhibitor is decarboxylase inhibitor and/or catechol O-methyltransferase inhibitor and/or oxidase inhibitor and/or B-hydroxylase inhibitors.
Such pharmaceutical composition be into-step is preferred, promptly wherein decarboxylase inhibitor is selected from D, L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides (benserazide), (-)-L-a-diazanyl-3,4-dihydroxy-a-hydrogenated methyl cinnamic acid (carbidopa), L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides, glycine-2-(2,3,4-trihydroxy benzyl) hydrazides and L-tyrosine-2-(2,3,4-trihydroxy benzyl) hydrazides with and physiological compatibility salt.
Such pharmaceutical composition is particularly advantageous, promptly wherein the catechol O-methyltransferase inhibitor be selected from entacapone and cabergoline with and physiological compatibility salt.
Such pharmaceutical composition is further favourable, promptly wherein oxidase inhibitor be selected from selegiline, moclobemide and tranylcypromine with and physiological compatibility salt.
In addition, such pharmaceutical composition is preferred, promptly wherein B-hydroxylase inhibitors be selected from 5-butyl picolinate calcium and 5-pentyl pyridine calcium formate with and physiological compatibility salt.
The preparation of L-DOPA and its derivant such as Arrcostab is that itself is known.
In order to prepare the physiological compatibility salt of L-DOPA and its derivant, can use the inorganic and organic acid of common physiological compatibility, example hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid.Other operable acid for example are described in " drug research progress (Fortschritte derArzneimittelforschung) ", the mat woven of fine bamboo strips 10 volumes, the 224-225 page or leaf, Birkh user publishing house, Basel and Stuttgart (1966), " pharmaceutical science magazine (Journal ofPharmaceutical Sciences) ", the 66th volume, mat woven of fine bamboo strips 1-5 page or leaf (1977).
The acid-addition salts of L-DOPA and its derivant obtains by free alkali or its solution are mixed in organic solvent with corresponding sour or its solution usually in known manner, this organic solvent for example is lower alcohol such as methanol, ethanol, normal propyl alcohol or isopropyl alcohol, perhaps lower ketones such as acetone, methyl ethyl ketone or methyl iso-butyl ketone (MIBK), perhaps ether such as ether, oxolane Huo diox.Separate out in order to obtain better crystal, can also use the mixture of described solvent.In addition, can also in aqueous acid solution, prepare physiological compatibility aqueous solution according to the acid-addition salts of chemical compound used in the present invention.
The acid-addition salts of L-DOPA and its derivant can be in known manner, for example uses alkali or ion-exchanger and be transformed into free alkali.From free alkali, by with inorganic or organic acid, particularly be fit to form treatment and go up the acid reaction of spendable salt and can obtain other salt.This or other salt such as the picrate of this new compound also can be used for the free alkali of purification, and this is by free alkali being changed salify, isolate this salt, and discharge alkali once more from this salt and finish.
Target of the present invention is also oral for being used for, oral cavity, Sublingual, nose, rectum, subcutaneous, intravenous or intramuscular administration, and the medicine that is used to suck, these medicines also contain L-DOPA, derivant or their acid-addition salts as active substance except containing common carrier and diluent.
Adopt known mode, prepare medicine of the present invention with common solid or liquid carrier material or diluent and the normally used and required corresponding pharmaceutical technology auxiliary agent of type of using with proper dosage.Preferred preparation exists to be suitable for Orally administered form of medication.Such form of medication for example is tablet, suction tablet, film coated tablet, dragee, capsule, pill, powder, solution, aerosol or suspension or long-acting form.
Self-evident, also can consider parenteral administration such as injection solution.In addition, for example also suppository is called preparation.
Corresponding tablet for example can obtain by active substance is mixed with known auxiliary agent, known auxiliary agent for example is inert diluent such as glucose, sugar, Sorbitol, mannitol, polyvinylpyrrolidone, disintegrating agent such as corn starch or alginic acid, binding agent such as starch or gelatin, lubricant such as magnesium stearate or Talcum and/or be used to obtain the reagent of long-acting effect such as carboxyl polymethylene, carboxymethyl cellulose, acetic acid-O-phthalic acid cellulose or polyvinyl acetate.Tablet can also multilamellar constitute.
Correspondingly, dragee (also comprising the dragee that is used for controlled or the dosage form that postpone to discharge) can prepare by following method, is about to be similar to nuclear that tablet makes and applies with the reagent that uses in the dragee coating usually such as polyvinylpyrrolidone or Lac, arabic gum, Talcum, titanium dioxide or sugar.At this, the dragee shell also can be made of multilamellar, wherein can use to regard to the described auxiliary agent of tablet.
The solution or the suspension that have according to active substance used in the present invention can also contain sense of taste improving agent such as glucide, cyclamate or sugar in addition, and for example aromatic substance such as vanillin or orange extract.In addition, they can also contain suspension aids such as sodium carboxymethyl cellulose, or antiseptic such as P-hydroxybenzoic acid.The capsule that contains active substance for example can so prepare, and is about to active substance and inert carrier such as lactose or Sorbitol and mixes, in the gelatine capsule of packing into then.
Suitable suppository for example can by with the carrier that is applicable to suppository, mix as neutral fat or Polyethylene Glycol or its derivant and to prepare.
The preparation of pharmaceutical preparation of the present invention is that itself is known, and is described in the known handbook of professional and technical personnel, Hager ' s Handbuch (5.) 2 for example, 622-1045; People such as List, Arzneiformenlehre, Stuttgart:Wiss. publishing house 1985; People such as Sucker, Pharmazeutische Technologie, Stuttgart:Thieme 1991; Ullmann ' s Enzyklop die (5.) A 19,241-271; Voigt, PharmazeutischeTechnologie, Berlin:Ullstein Mosby 1995.
The following examples have been explained the present invention:
Embodiment
10 patients that suffer from acute schizophrenia have accepted to use keeping treatment and keeping stable clinically of fluphenazine after ill in year, end treatment subsequently.According to clinical experience (referring to Gitlin M., Nuechterlein K., people such as Subotnik K.L., Am.J.Psychiatry (2001) 158 (11), the 1835-42 page or leaf), once recurrence appears in about 8 meetings that are expected among 10 patients in subsequently 12 months.Our patient before stopping to keep treatment 2 months and treat with L-DOPA or the combination formulations that contains the L-DOPA during keeping the treatment adjourning whole.In these patients, only recurrence has appearred in 2 in 10 cases.
Claims (8)
1.L-DOPA, its derivant and their physiological compatibility salt are used to prevent psychosis particularly schizophrenia and the purposes that is used for the treatment of the disease that causes owing to disorderly tyrosine transhipment or disorderly tyrosine decarboxylase.
2.L-DOPA, its derivant and their physiological compatibility salt are used to prepare the purposes of medicine, this medicine is used to prevent particularly schizophrenia and be used for the treatment of the disease that causes owing to disorderly tyrosine transhipment or disorderly tyrosine decarboxylase of psychosis.
3. according to the purposes of L-DOPA, its derivant and their the physiological compatibility salt of claim 1 or 2, it unites at least a enzyme inhibitor.
4. according to the purposes of L-DOPA, its derivant and their the physiological compatibility salt of claim 3, it is characterized in that this enzyme inhibitor is decarboxylase inhibitor and/or catechol O-methyltransferase inhibitor and/or oxidase inhibitor and/or B-hydroxylase inhibitors.
5. according to the purposes of L-DOPA, its derivant and their the physiological compatibility salt of claim 4, it is characterized in that, decarboxylase inhibitor is selected from D, L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides (benserazide), (-)-L-a-diazanyl-3,4-dihydroxy-a-hydrogenated methyl cinnamic acid (carbidopa), L-serine-2-(2,3,4-trihydroxy benzyl) hydrazides, glycine-2-(2,3,4-trihydroxy benzyl) hydrazides and L-tyrosine-2-(2,3,4-trihydroxy benzyl) hydrazides and physiological compatibility salt thereof.
6. according to the purposes of L-DOPA, its derivant and their the physiological compatibility salt of claim 4, it is characterized in that the catechol O-methyltransferase inhibitor is selected from entacapone and cabergoline and physiological compatibility salt thereof.
7. according to the purposes of L-DOPA, its derivant and their the physiological compatibility salt of claim 4, it is characterized in that oxidase inhibitor is selected from selegiline, moclobemide and tranylcypromine and physiological compatibility salt thereof.
8. according to the purposes of L-DOPA, its derivant and their the physiological compatibility salt of claim 4, it is characterized in that, B-hydroxylase inhibitors be selected from 5-butyl picolinate calcium and 5-pentyl pyridine calcium formate with and physiological compatibility salt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10261808A DE10261808A1 (en) | 2002-12-19 | 2002-12-19 | Use of L-DOPA, its derivatives and medicaments containing these compounds for the prophylaxis of psychotic diseases |
| DE10261808.9 | 2002-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1756542A true CN1756542A (en) | 2006-04-05 |
Family
ID=32478131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2003801066148A Pending CN1756542A (en) | 2002-12-19 | 2003-12-18 | Use of L-dopa, derivatives thereof and medicaments containing said compounds for the prevention of psychotic disorders |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1615631A2 (en) |
| JP (1) | JP2006511558A (en) |
| CN (1) | CN1756542A (en) |
| AU (1) | AU2003294664A1 (en) |
| CA (1) | CA2513077A1 (en) |
| DE (1) | DE10261808A1 (en) |
| EA (1) | EA200500957A1 (en) |
| MX (1) | MXPA05006409A (en) |
| PL (1) | PL377524A1 (en) |
| WO (1) | WO2004056306A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078952A (en) * | 2015-08-10 | 2015-11-25 | 中国康复研究中心 | Levodopa preparation and application thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401842D0 (en) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| USRE46555E1 (en) * | 2006-02-17 | 2017-09-19 | Teva Pharmaceuticals International Gmbh | Deuterated catecholamine derivatives and medicaments comprising said compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52102431A (en) * | 1976-02-25 | 1977-08-27 | Kyowa Hakko Kogyo Co Ltd | Remedies for mental disorder |
| IE47082B1 (en) * | 1977-07-01 | 1983-12-14 | Merrell Toraude & Co | -acetylenic amino acids |
| US5149786A (en) * | 1989-10-12 | 1992-09-22 | Chiron Corporation | Dopamine releasing protein and antibody |
-
2002
- 2002-12-19 DE DE10261808A patent/DE10261808A1/en not_active Ceased
-
2003
- 2003-12-18 WO PCT/DE2003/004204 patent/WO2004056306A2/en not_active Application Discontinuation
- 2003-12-18 JP JP2004561055A patent/JP2006511558A/en active Pending
- 2003-12-18 EA EA200500957A patent/EA200500957A1/en unknown
- 2003-12-18 EP EP03785594A patent/EP1615631A2/en not_active Withdrawn
- 2003-12-18 CN CNA2003801066148A patent/CN1756542A/en active Pending
- 2003-12-18 MX MXPA05006409A patent/MXPA05006409A/en unknown
- 2003-12-18 AU AU2003294664A patent/AU2003294664A1/en not_active Abandoned
- 2003-12-18 PL PL377524A patent/PL377524A1/en not_active Application Discontinuation
- 2003-12-18 CA CA002513077A patent/CA2513077A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078952A (en) * | 2015-08-10 | 2015-11-25 | 中国康复研究中心 | Levodopa preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004056306A2 (en) | 2004-07-08 |
| MXPA05006409A (en) | 2006-05-31 |
| DE10261808A1 (en) | 2004-07-08 |
| PL377524A1 (en) | 2006-02-06 |
| EP1615631A2 (en) | 2006-01-18 |
| WO2004056306A3 (en) | 2004-11-11 |
| JP2006511558A (en) | 2006-04-06 |
| EA200500957A1 (en) | 2006-02-24 |
| AU2003294664A1 (en) | 2004-07-14 |
| CA2513077A1 (en) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5185488B2 (en) | 2- (4-Isobutylphenyl) propionic acid pharmaceutical composition | |
| US8455667B2 (en) | Duloxetine compositions in the form of a powder for suspension in a liquid | |
| TW200815007A (en) | Formulations for parenteral delivery of compounds and uses thereof | |
| US20030130314A1 (en) | Analgesic delivery systems and methods of use | |
| KR101915056B1 (en) | Liquidic formulation for oral administraion comprising ambroxol, levodropropizine and buffer, and method for preparing the same | |
| JP2020536926A (en) | Stabilized pharmaceutical composition for L-epinephrine | |
| EP2608789B1 (en) | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine | |
| JP2005531612A (en) | Nefopam formulation and its use in the treatment of pain | |
| CN1756542A (en) | Use of L-dopa, derivatives thereof and medicaments containing said compounds for the prevention of psychotic disorders | |
| US6194466B1 (en) | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications | |
| KR20140118412A (en) | Slow release pharmaceutical composition having Eperisone as active ingredient | |
| EP2848261B1 (en) | Pharmaceutical formulations comprising a muscle relaxant and an analgesic combination | |
| CA3191145A1 (en) | Therapeutic agent and nutraceutical compositions and methods for making and using same | |
| EP3996699B1 (en) | Combination of ibuprofen and tramadol for relieving pain | |
| US6335372B1 (en) | Treatment of obsessive compulsive disorder | |
| JPH07507280A (en) | (-)-Metriphonate-containing drugs | |
| US20070082953A1 (en) | Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases | |
| TW201728326A (en) | New use of isoquinoline derivatives for diabetic wound healing | |
| WO2023201390A1 (en) | Aqueous quetiapine solutions | |
| WO2024010935A1 (en) | Compositions of aspirin and ketamine | |
| CA3212160A1 (en) | Tasipimidine formulations and use thereof | |
| BR112015018952B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DEXKETOPROFENE AND TRAMADOL, THEIR MANUFACTURING METHOD AND THEIR USE | |
| TW200816995A (en) | Pharmaceutical composition containing insulin sensitizers | |
| TW200403989A (en) | Methods and compositions for treatment of cancer pain | |
| CN1355696A (en) | Method to aid smoking cessation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1087029 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1087029 Country of ref document: HK |